Compare NICE Ltd (NICE) vs 10X Genomics Inc (TXG) Price & Performance

NICE trades at $116.83, up 0.35% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $124.20. The company reported strong Q2 2026 earnings, beating EPS estimates with $2.70 actual versus $2.63 expected, and was recently named a leader in the IDC MarketScape for contact center platforms (Business Wire, 2026-10-01). Revenue for 2025 was $2.95 billion with a net income margin of 20.78%.

The outlook is positive, supported by AI-driven growth and a reasonable valuation with a P/E of 17.08. However, risks include margin compression from increased investment and potential market volatility. Analyst sentiment is bullish with 12 buy ratings and no sells, but investors should monitor execution on AI initiatives and competitive pressures in the CX software space.

10x Genomics (TXG) trades at $82.37, up 8.24% over 24 hours, with a bearish technical signal and mixed analyst sentiment. The company reported a net loss of $43.54M in 2025, but revenue grew to $642.82M, and it has beaten EPS estimates for three consecutive quarters. Recent news highlights strong demand for its Atera platform and a patent victory, though profitability remains a challenge.

The outlook is cautiously optimistic, with growth potential from new product launches and spatial biology demand, but risks include persistent losses, high valuation multiples, and competitive pressures. The consensus price target is $74.30, below the current price, suggesting limited near-term upside.